Disease Flare with Gonadotrophin-Releasing Hormone (GnRH) Analogues

@article{Scaletscky1993DiseaseFW,
  title={Disease Flare with Gonadotrophin-Releasing Hormone (GnRH) Analogues},
  author={R. Scaletscky and J. A. Smith},
  journal={Drug Safety},
  year={1993},
  volume={8},
  pages={265-270}
}
View on Springer
ncbi.nlm.nih.gov
4 Citations
Background Citations
1

Topics from this paper

    4 Citations

    Citation Type

    Citation Type

    Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    • 19
    A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer
    • 39
    A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
    • 95
    Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
    • 116

    References

    SHOWING 1-10 OF 22 REFERENCES
    Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
    • 171
    Priapism in hypogonadal men receiving gonadotropin releasing hormone.
    • 6
    Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    • 66
    Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.
    • 108
    A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
    • 1,376
    Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
    • 27
    Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
    • 172
    Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    • 181
    A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate
    • 42
    Endocrine and Clinical Evaluation of 107 Patients With Advanced Prostatic Carcinoma Under Long‐Term Pernasal Buserelin or Intramuscular Decapeptyl Depot Treatment
    • 11
    ...
    1
    2
    3
    ...